AK and A: Writing—review & editing, Conceptualization, Validation, Methodology, Formal analysis, Writing—original draft. Both authors read and approved the submitted version.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Kalathoor S, Rajendran S, Canella A, Raval R, Cripe TP, Mardis ER, et al. Myeloid cell heterogeneity in the tumor microenvironment and therapeutic implications for childhood central nervous system (CNS) tumors.J Neuroimmunol. 2023;374:578009. [DOI] [PubMed]
Smith HL, Wadhwani N, Horbinski C. Major Features of the 2021 WHO Classification of CNS Tumors.Neurotherapeutics. 2022;19:1691–704. [DOI] [PubMed] [PMC]
Singh S, Dey D, Barik D, Mohapatra I, Kim S, Sharma M, et al. Glioblastoma at the crossroads: current understanding and future therapeutic horizons.Signal Transduct Target Ther. 2025;10:213. [DOI] [PubMed] [PMC]
Melhem JM, Detsky J, Lim-Fat MJ, Perry JR. Updates in IDH-Wildtype Glioblastoma.Neurotherapeutics. 2022;19:1705–23. [DOI] [PubMed] [PMC]
Sipos D, Raposa BL, Freihat O, Simon M, Mekis N, Cornacchione P, et al. Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes.Cancers (Basel). 2025;17:146. [DOI] [PubMed] [PMC]
Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A, et al. Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies.Mol Cancer. 2025;24:58. [DOI] [PubMed] [PMC]
Bailey S, Jacobs S, Kourti M, Massimino M, Andre N, Doz F, et al. Medulloblastoma Therapy: Consensus Treatment Recommendations from SIOP-Europe and the European Reference Network.EJC Paediatr Oncol. 2025;5:100205. [DOI]
Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, et al. Molecular subgroups of medulloblastoma: the current consensus.Acta Neuropathol. 2012;123:465–72. [DOI] [PubMed] [PMC]
Sursal T, Ronecker JS, Dicpinigaitis AJ, Mohan AL, Tobias ME, Gandhi CD, et al. Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions.Anticancer Res. 2022;42:2225–39. [DOI] [PubMed]
Wang RC, Wang Z. Precision Medicine: Disease Subtyping and Tailored Treatment.Cancers (Basel). 2023;15:3837. [DOI] [PubMed] [PMC]
Johnsen JI, Kogner P. Recent Advances in Neuroblastoma Research.Cancers (Basel). 2024;16:812. [DOI] [PubMed] [PMC]
Alaseem AM, Alrehaili JA. Overcoming the blood-brain barrier (BBB) in pediatric CNS tumors: immunotherapy and nanomedicine-driven strategies.Med Oncol. 2025;42:431. [DOI] [PubMed]
Mo F, Pellerino A, Soffietti R, Rudà R. Blood-Brain Barrier in Brain Tumors: Biology and Clinical Relevance.Int J Mol Sci. 2021;22:12654. [DOI] [PubMed] [PMC]
Atanasov AG, Zotchev SB, Dirsch VM, International Natural Product Sciences Taskforce, Supuran CT. Natural products in drug discovery: advances and opportunities.Nat Rev Drug Discov. 2021;20:200–16. [DOI] [PubMed] [PMC]
Izzo AA, Stefanska B. Natural products and cancer: From drug discovery to prevention and therapy.Br J Pharmacol. 2025;182:2069–74. [DOI] [PubMed]
Ghosh S, Das SK, Sinha K, Ghosh B, Sen K, Ghosh N, et al. The Emerging Role of Natural Products in Cancer Treatment.Arch Toxicol. 2024;98:2353–91. [DOI] [PubMed]
Naeem A, Hu P, Yang M, Zhang J, Liu Y, Zhu W, et al. Natural Products as Anticancer Agents: Current Status and Future Perspectives.Molecules. 2022;27:8367. [DOI] [PubMed] [PMC]
Chagas MdSS, Behrens MD, Moragas-Tellis CJ, Penedo GXM, Silva AR, Gonçalves-de-Albuquerque CF. Flavonols and Flavones as Potential anti-Inflammatory, Antioxidant, and Antibacterial Compounds.Oxid Med Cell Longev. 2022;2022:9966750. [DOI] [PubMed] [PMC]
Pisoschi AM, Iordache F, Stanca L, Cimpeanu C, Furnaris F, Geicu OI, et al. Comprehensive and critical view on the anti-inflammatory and immunomodulatory role of natural phenolic antioxidants.Eur J Med Chem. 2024;265:116075. [DOI] [PubMed]
Al-Khayri JM, Sahana GR, Nagella P, Joseph BV, Alessa FM, Al-Mssallem MQ. Flavonoids as Potential Anti-Inflammatory Molecules: A Review.Molecules. 2022;27:2901. [DOI] [PubMed] [PMC]
Hashem S, Ali TA, Akhtar S, Nisar S, Sageena G, Ali S, et al. Targeting cancer signaling pathways by natural products: Exploring promising anti-cancer agents.Biomed Pharmacother. 2022;150:113054. [DOI] [PubMed]
Khan N, Syed DN, Ahmad N, Mukhtar H. Fisetin: a dietary antioxidant for health promotion.Antioxid Redox Signal. 2013;19:151–62. [DOI] [PubMed] [PMC]
Zhang XJ, Jia SS. Fisetin inhibits laryngeal carcinoma through regulation of AKT/NF-κB/mTOR and ERK1/2 signaling pathways.Biomed Pharmacother. 2016;83:1164–74. [DOI] [PubMed]
Antika LD, Dewi RM. Pharmacological Aspects of Fisetin.Asian Pac J Trop Biomed. 2021;11:1–9. [DOI]
Khan S, Khan MM, Badruddeen, Ahmad U, Khan S. Fisetin as a Multifunctional Bioactive Flavonoid: A Comprehensive Review of Its Pharmacology, Mechanism of Action, Safety Profile, Clinical Trials, and Future Directions in Therapeutics.Food Biosci. 2025;73:107620. [DOI]
Imran M, Saeed F, Gilani SA, Shariati MA, Imran A, Afzaal M, et al. Fisetin: An anticancer perspective.Food Sci Nutr. 2020;9:3–16. [DOI] [PubMed] [PMC]
Adhami VM, Syed DN, Khan N, Mukhtar H. Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management.Biochem Pharmacol. 2012;84:1277–81. [DOI] [PubMed] [PMC]
George VC. Promising tumor inhibiting potentials of Fisetin through PI3K/AKT/mTOR pathway.Am J Transl Res. 2016;8:1293–4. [PubMed] [PMC]
Krishnakumar IM, Jaja-Chimedza A, Joseph A, Balakrishnan A, Maliakel B, Swick A. Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals: a randomised double-blinded comparative crossover study.J Nutr Sci. 2022;11:e74. [DOI] [PubMed] [PMC]
Hassan SSU, Samanta S, Dash R, Karpiński TM, Habibi E, Sadiq A, et al. The neuroprotective effects of fisetin, a natural flavonoid in neurodegenerative diseases: Focus on the role of oxidative stress.Front Pharmacol. 2022;13:1015835. [DOI] [PubMed] [PMC]
Rengarajan T, Yaacob NS. The flavonoid fisetin as an anticancer agent targeting the growth signaling pathways.Eur J Pharmacol. 2016;789:8–16. [DOI] [PubMed]
Szymczak J, Cielecka-Piontek J. Fisetin-In Search of Better Bioavailability-From Macro to Nano Modifications: A Review.Int J Mol Sci. 2023;24:14158. [DOI] [PubMed] [PMC]
Telrandhe UB, Hasnain AN, Kothawade SN, Telange DR. Recent advancement of fisetin-based nanoformulations in the management of psoriasis.Discov Nano. 2025;20:105. [DOI] [PubMed] [PMC]
Harborne JB. Progress in the Chemistry of Organic Natural Products.Phytochemistry. 1975;14:1470–1. [DOI]
Touil YS, Fellous A, Scherman D, Chabot GG. Flavonoid-induced morphological modifications of endothelial cells through microtubule stabilization.Nutr Cancer. 2009;61:310–21. [DOI] [PubMed] [PMC]
Pal HC, Pearlman RL, Afaq F. Fisetin and Its Role in Chronic Diseases.Adv Exp Med Biol. 2016;928:213–44. [DOI] [PubMed]
Kim SH, Huh CK. Isolation and Identification of Fisetin: An Antioxidative Compound Obtained from Rhus verniciflua Seeds.Molecules. 2022;27:4510. [DOI] [PubMed] [PMC]
Mehta P, Pawar A, Mahadik K, Bothiraja C. Emerging novel drug delivery strategies for bioactive flavonol fisetin in biomedicine.Biomed Pharmacother. 2018;106:1282–91. [DOI] [PubMed]
Elwan AH, El-Masry SM, Habib DA, Zewail M. An Insight into Fisetin, the Miraculous Multifaceted Flavonol: Paving the Road for Enhanced Delivery through Promising Pharmaceutical Nano-Formulations.J Drug Deliv Sci Technol. 2024;101:106292. [DOI]
Kim SB, Bisson J, Friesen JB, Pauli GF, Simmler C. Selective Chlorophyll Removal Method to “Degreen” Botanical Extracts.J Nat Prod. 2020;83:1846–58. [DOI] [PubMed] [PMC]
Sawant SS, Park HY, Sim EY, Kim HS, Choi HS. Microbial Fermentation in Food: Impact on Functional Properties and Nutritional Enhancement—A Review of Recent Developments.Fermentation. 2025;11:15. [DOI]
Zhong R, Farag MA, Chen M, He C, Xiao J. Recent Advances in the Biosynthesis, Structure–Activity Relationships, Formulations, Pharmacology, and Clinical Trials of Fisetin.eFood. 2022;3:e3. [DOI]
Sobczak A, Dominiak K, Sztenc B, Jadach B, Woźniak-Braszak A, Baranowski M, et al. Anticancer Potential of Fisetin Against Glioblastoma: In vitro Evaluation, Radiostability Assessment, and Preliminary PLGA Encapsulation.Polymers (Basel). 2025;17:3074. [DOI] [PubMed] [PMC]
Beltzig L, Christmann M, Dobreanu M, Kaina B. Genotoxic and Cytotoxic Activity of Fisetin on Glioblastoma Cells.Anticancer Res. 2024;44:901–10. [DOI] [PubMed]
Pak F, Oztopcu-Vatan P. Fisetin effects on cell proliferation and apoptosis in glioma cells.Z Naturforsch C J Biosci. 2019;74:295–302. [DOI] [PubMed]
Chen CM, Hsieh YH, Hwang JM, Jan HJ, Hsieh SC, Lin SH, et al. Fisetin suppresses ADAM9 expression and inhibits invasion of glioma cancer cells through increased phosphorylation of ERK1/2.Tumor Biol. 2015;36:3407–15. [DOI] [PubMed]
Renault-Mahieux M, Vieillard V, Seguin J, Espeau P, Le DT, Lai-Kuen R, et al. Co-Encapsulation of Fisetin and Cisplatin into Liposomes for Glioma Therapy: From Formulation to Cell Evaluation.Pharmaceutics. 2021;13:970. [DOI] [PubMed] [PMC]
Liu Y, Chu W, Ma H, Peng W, Li Q, Han L, et al. Fisetin orchestrates neuroinflammation resolution and facilitates spinal cord injury recovery through enhanced autophagy in pro-inflammatory glial cells.Int Immunopharmacol. 2024;130:111738. [DOI] [PubMed]
Kumar R, Kumar R, Khurana N, Singh SK, Khurana S, Verma S, et al. Enhanced oral bioavailability and neuroprotective effect of fisetin through its SNEDDS against rotenone-induced Parkinson’s disease rat model.Food Chem Toxicol. 2020;144:111590. [DOI] [PubMed]
Cordaro M, D’Amico R, Fusco R, Peritore AF, Genovese T, Interdonato L, et al. Discovering the Effects of Fisetin on NF-κB/NLRP-3/NRF-2 Molecular Pathways in a Mouse Model of Vascular Dementia Induced by Repeated Bilateral Carotid Occlusion.Biomedicines. 2022;10:1448. [DOI] [PubMed] [PMC]
Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis.J Hematol Oncol. 2022;15:129. [DOI] [PubMed] [PMC]
Zhang R, Takigawa H, Maruyama H, Nambu T, Mashimo C, Okinaga T. Fisetin Inhibits Periodontal Pathogen-Induced EMT in Oral Squamous Cell Carcinoma via the Wnt/β-Catenin Pathway.Nutrients. 2025;17:3522. [DOI] [PubMed] [PMC]
Kim N, Kwon J, Shin US, Jung J. Fisetin induces the upregulation of AKAP12 mRNA and anti-angiogenesis in a patient-derived organoid xenograft model.Biomed Pharmacother. 2023;167:115613. [DOI] [PubMed]
Wang W, Zhang Y, Jian Y, He S, Liu J, Cheng Y, et al. Sensitizing chemotherapy for glioma with fisetin mediated by a microenvironment-responsive nano-drug delivery system.Nanoscale. 2023;16:97–109. [DOI] [PubMed]
Ferah S, Çamlibel M, Erçelik M, Tekin Ç, Tezcan G, Gürbüz M, et al. Overcoming Intrinsic and Acquired Temozolomide Resistance in Glioblastoma: Fisetin as a Potential Strategy to Enhance Sensitivity via ZEB1 Modulation.Turk J Pharm Sci. 2026;22:367–80. [DOI] [PubMed] [PMC]
Zhang S, Xue R, Geng Y, Wang H, Li W. Fisetin Prevents HT22 Cells From High Glucose-Induced Neurotoxicity via PI3K/Akt/CREB Signaling Pathway.Front Neurosci. 2020;14:241. [DOI] [PubMed] [PMC]
Afroze N, Pramodh S, Shafarin J, Bajbouj K, Hamad M, Sundaram MK, et al. Fisetin Deters Cell Proliferation, Induces Apoptosis, Alleviates Oxidative Stress and Inflammation in Human Cancer Cells, HeLa.Int J Mol Sci. 2022;23:1707. [DOI] [PubMed] [PMC]
Yang T, Gou H, Lin T, Yang Y, Jin X, Dong T, et al. Fisetin nanoparticles based on cells cycle and apoptosis intervention for the treatment of lymphoma and leukemia.Int J Pharm. 2024;654:123971. [DOI] [PubMed]
Rahmani AH, Almatroudi A, Allemailem KS, Khan AA, Almatroodi SA. The Potential Role of Fisetin, a Flavonoid in Cancer Prevention and Treatment.Molecules. 2022;27:9009. [DOI] [PubMed] [PMC]
Sattari M, Amri J, Shahaboddin ME, Sattari M, Tabatabaei-Malazy O, Azmon M, et al. The protective effects of fisetin in metabolic disorders: a focus on oxidative stress and associated events.J Diabetes Metab Disord. 2024;23:1753–71. [DOI] [PubMed] [PMC]
Li J, Li W, Huang M, Zhang X. Fisetin, a Dietary Flavonoid Induces Apoptosis via Modulating the MAPK and PI3K/Akt Signalling Pathways in Human Osteosarcoma (U-2 OS) Cells.Bangladesh J Pharmacol. 2015;10:820–9. [DOI]
Lim JY, Lee JY, Byun BJ, Kim SH. Fisetin targets phosphatidylinositol-3-kinase and induces apoptosis of human B lymphoma Raji cells.Toxicol Rep. 2015;2:984–9. [DOI] [PubMed] [PMC]
Yadav M, Kandhari K, Mathan SV, Ali M, Singh RP. Fisetin induces G2/M phase arrest and caspase-mediated cleavage of p21Cip1 and p27Kip1 leading to apoptosis and tumor growth inhibition in HNSCC.Mol Carcinog. 2024;63:1697–711. [DOI] [PubMed]
Yang H, Hong Y, Gong M, Cai S, Yuan Z, Feng S, et al. Fisetin exerts neuroprotective effects in vivo and in vitro by inhibiting ferroptosis and oxidative stress after traumatic brain injury.Front Pharmacol. 2024;15:1480345. [DOI] [PubMed] [PMC]
Alamoudi A, Alqarni K, Khayyat AIA, Hussain T, Alamery S. Modulation of PI3K/AKT/mTOR and apoptosis pathway in colon cancer cells by the plant flavonoid fisetin.PeerJ. 2025;13:e20225. [DOI] [PubMed] [PMC]
Watanabe R, Kurose T, Morishige Y, Fujimori K. Protective effects of fisetin against 6-OHDA-induced apoptosis by activation of PI3K-Akt signaling in human neuroblastoma SH-SY5Y cells.Neurochem Res. 2018;43:488–99. [DOI] [PubMed]
Jang HY, Kim GB, Kim JM, Kang SY, Youn HJ, Park J, et al. Fisetin Inhibits UVA-Induced Expression of MMP-1 and MMP-3 through the NOX/ROS/MAPK Pathway in Human Dermal Fibroblasts and Human Epidermal Keratinocytes.Int J Mol Sci. 2023;24:17358. [DOI] [PubMed] [PMC]
Kumar RM, Kumar H, Bhatt T, Jain R, Panchal K, Chaurasiya A, et al. Fisetin in Cancer: Attributes, Developmental Aspects, and Nanotherapeutics.Pharmaceuticals (Basel). 2023;16:196. [DOI] [PubMed] [PMC]
Kubina R, Krzykawski K, Kabała-Dzik A, Wojtyczka RD, Chodurek E, Dziedzic A. Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review.Nutrients. 2022;14:2604. [DOI] [PubMed] [PMC]
Chen T, You Y, Jiang H, Wang ZZ. Epithelial-mesenchymal transition (EMT): A biological process in the development, stem cell differentiation, and tumorigenesis.J Cell Physiol. 2017;232:3261–72. [DOI] [PubMed] [PMC]
Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, et al. The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges.Cells. 2019;8:1118. [DOI] [PubMed] [PMC]
Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition.Sci Signal. 2014;7:re8. [DOI] [PubMed] [PMC]
Park JH, Jang YJ, Choi YJ, Jang JW, Kim JH, Rho YK, et al. Fisetin inhibits matrix metalloproteinases and reduces tumor cell invasiveness and endothelial cell tube formation.Nutr Cancer. 2013;65:1192–9. [DOI] [PubMed]
Zhou C, Huang Y, Nie S, Zhou S, Gao X, Chen G. Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent.Eur J Med Res. 2023;28:297. [DOI] [PubMed] [PMC]
Maher P. How fisetin reduces the impact of age and disease on CNS function.Front Biosci (Schol Ed). 2015;7:58–82. [DOI] [PubMed] [PMC]
Fatima R, Soni P, Sharma M, Prasher P, Kaverikana R, Mangalpady SS, et al. Fisetin as a chemoprotective and chemotherapeutic agent: mechanistic insights and future directions in cancer therapy.Med Oncol. 2025;42:104. [DOI] [PubMed]
Bhat TA, Nambiar D, Pal A, Agarwal R, Singh RP. Fisetin inhibits various attributes of angiogenesis in vitro and in vivo--implications for angioprevention.Carcinogenesis. 2012;33:385–93. [DOI] [PubMed]
Biray Avci C, Goker Bagca B, Nikanfar M, Takanlou LS, Takanlou MS, Nourazarian A. Tumor microenvironment and cancer metastasis: molecular mechanisms and therapeutic implications.Front Pharmacol. 2024;15:1442888. [DOI] [PubMed] [PMC]
Bożyk A, Wojas-Krawczyk K, Krawczyk P, Milanowski J. Tumor Microenvironment-A Short Review of Cellular and Interaction Diversity.Biology (Basel). 2022;11:929. [DOI] [PubMed] [PMC]
Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities.Cell Mol Life Sci. 2020;77:1745–70. [DOI] [PubMed] [PMC]
Parihar A, Mishra A, Palei NN. Fisetin: An Extensive Analysis of Its Therapeutic Potential and Pharmacological Properties.J Mt Res. 2025;20:409–15. [DOI]
Ferrer VP, Moura Neto V, Mentlein R. Glioma infiltration and extracellular matrix: key players and modulators.Glia. 2018;66:1542–65. [DOI] [PubMed]
Wang L, Chen N, Cheng H. Fisetin inhibits vascular endothelial growth factor-induced angiogenesis in retinoblastoma cells.Oncol Lett. 2020;20:1239–44. [DOI] [PubMed] [PMC]
Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics.Genes Dis. 2022;10:1367–401. [DOI] [PubMed] [PMC]
Rudzińska A, Juchaniuk P, Oberda J, Wiśniewska J, Wojdan W, Szklener K, et al. Phytochemicals in Cancer Treatment and Cancer Prevention-Review on Epidemiological Data and Clinical Trials.Nutrients. 2023;15:1896. [DOI] [PubMed] [PMC]
Riviere-Cazaux C, Carlstrom LP, Neth BJ, Olson IE, Rajani K, Rahman M, et al. An untapped window of opportunity for glioma: targeting therapy-induced senescence prior to recurrence.NPJ Precis Oncol. 2023;7:126. [DOI] [PubMed] [PMC]
Liu B, Zhou H, Tan L, Siu KTH, Guan X. Exploring treatment options in cancer: Tumor treatment strategies.Signal Transduct Target Ther. 2024;9:175. [DOI] [PubMed] [PMC]
Majidinia M, Mirza-Aghazadeh-Attari M, Rahimi M, Mihanfar A, Karimian A, Safa A, et al. Overcoming Multidrug Resistance in Cancer: Recent Progress in Nanotechnology and New Horizons.IUBMB Life. 2020;72:855–71. [DOI]
Mukhtar E, Adhami VM, Siddiqui IA, Verma AK, Mukhtar H. Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells.Mol Cancer Ther. 2016;15:2863–74. [DOI] [PubMed] [PMC]
Tripathi R, Samadder T, Gupta S, Surolia A, Shaha C. Anticancer activity of a combination of cisplatin and fisetin in embryonal carcinoma cells and xenograft tumors.Mol Cancer Ther. 2011;10:255–68. [DOI] [PubMed]
Ferreira de Oliveira JMP, Pacheco AR, Coutinho L, Oliveira H, Pinho S, Almeida L, et al. Combination of etoposide and fisetin results in anti-cancer efficiency against osteosarcoma cell models.Arch Toxicol. 2018;92:1205–14. [DOI] [PubMed]
Glassman PM, Muzykantov VR. Pharmacokinetic and Pharmacodynamic Properties of Drug Delivery Systems.J Pharmacol Exp Ther. 2019;370:570–80. [DOI] [PubMed] [PMC]
Sundarraj K, Raghunath A, Perumal E. A review on the chemotherapeutic potential of fisetin: In vitro evidences.Biomed Pharmacother. 2018;97:928–40. [DOI] [PubMed]
Feng C, Yuan X, Chu K, Zhang H, Ji W, Rui M. Preparation and optimization of poly (lactic acid) nanoparticles loaded with fisetin to improve anti-cancer therapy.Int J Biol Macromol. 2019;125:700–10. [DOI] [PubMed]
Yang Q, Liao J, Deng X, Liang J, Long C, Xie C, et al. Anti-Tumor Activity and Safety Evaluation of Fisetin-Loaded Methoxy Poly(Ethylene Glycol)–Poly(Ε-Caprolactone) Nanoparticles.J Biomed Nanotechnol. 2014;10:580–91. [DOI]
Chen L, Xu P, Fu C, Kankala RK, Chen A, Wang S. Fabrication of Supercritical Antisolvent (SAS) Process-Assisted Fisetin-Encapsulated Poly (Vinyl Pyrrolidone) (PVP) Nanocomposites for Improved Anticancer Therapy.Nanomaterials (Basel). 2020;10:322. [DOI] [PubMed] [PMC]
Sechi M, Syed DN, Pala N, Mariani A, Marceddu S, Brunetti A, et al. Nanoencapsulation of dietary flavonoid fisetin: Formulation and in vitro antioxidant and α-glucosidase inhibition activities.Mater Sci Eng C Mater Biol Appl. 2016;68:594–602. [DOI] [PubMed]
Liu W, Lin C, Hsieh Y, Wu Y. Nanoformulation Development to Improve the Biopharmaceutical Properties of Fisetin Using Design of Experiment Approach.Molecules. 2021;26:3031. [DOI] [PubMed] [PMC]
Chen Y, Wu Q, Song L, He T, Li Y, Li L, et al. Polymeric micelles encapsulating fisetin improve the therapeutic effect in colon cancer.ACS Appl Mater Interfaces. 2015;7:534–42. [DOI] [PubMed]
Xiao X, Zou J, Fang Y, Meng Y, Xiao C, Fu J, et al. Fisetin and polymeric micelles encapsulating fisetin exhibit potent cytotoxic effects towards ovarian cancer cells.BMC Complement Altern Med. 2018;18:91. [DOI] [PubMed] [PMC]
Wang L, Zhang D, Wang Y. Bioflavonoid Fisetin Loaded α-Tocopherol-Poly(lactic acid)-Based Polymeric Micelles for Enhanced Anticancer Efficacy in Breast Cancers.Pharm Res. 2017;34:453–61. [DOI] [PubMed]
Pawar A, Singh S, Rajalakshmi S, Shaikh K, Bothiraja C. Development of fisetin-loaded folate functionalized pluronic micelles for breast cancer targeting.Artif Cells Nanomed Biotechnol. 2018;46:347–61. [DOI] [PubMed]
Shah S, Patel AA, Prajapati BG, Alexander A, Pandya V, Trivedi N, et al. Multifaceted Nanolipidic Carriers: A Modish Stratagem Accentuating Nose-to-Brain Drug Delivery.J Nanoparticle Res. 2023;25:150. [DOI]
Koo J, Lim C, Oh KT. Recent Advances in Intranasal Administration for Brain-Targeting Delivery: A Comprehensive Review of Lipid-Based Nanoparticles and Stimuli-Responsive Gel Formulations.Int J Nanomedicine. 2024;19:1767–807. [DOI] [PubMed] [PMC]
Handa M, Beg S, Shukla R, Barkat MA, Choudhry H, Singh KK. Recent advances in lipid-engineered multifunctional nanophytomedicines for cancer targeting.J Control Release. 2021;340:48–59. [DOI] [PubMed]
M NK, S S, P SR, Narayanasamy D. The Science of Solid Lipid Nanoparticles: From Fundamentals to Applications.Cureus. 2024;16:e68807. [DOI] [PubMed] [PMC]
Kulbacka J, Pucek A, Kotulska M, Dubińska-Magiera M, Rossowska J, Rols M, et al. Electroporation and lipid nanoparticles with cyanine IR-780 and flavonoids as efficient vectors to enhanced drug delivery in colon cancer.Bioelectrochemistry. 2016;110:19–31. [DOI] [PubMed]
Bothiraja C, Yojana BD, Pawar AP, Shaikh KS, Thorat UH. Fisetin-loaded nanocochleates: formulation, characterisation, in vitro anticancer testing, bioavailability and biodistribution study.Expert Opin Drug Deliv. 2014;11:17–29. [DOI] [PubMed]
Currais A, Prior M, Dargusch R, Armando A, Ehren J, Schubert D, et al. Modulation of p25 and inflammatory pathways by fisetin maintains cognitive function in Alzheimer's disease transgenic mice.Aging Cell. 2014;13:379–90. [DOI] [PubMed] [PMC]
Blakeley J. Drug delivery to brain tumors.Curr Neurol Neurosci Rep. 2008;8:235–41. [DOI] [PubMed] [PMC]
Won DH, Chung SH, Shin JA, Hong KO, Yang IH, Yun JW, et al. Induction of sestrin 2 is associated with fisetin-mediated apoptosis in human head and neck cancer cell lines.J Clin Biochem Nutr. 2019;64:97–105. [DOI] [PubMed] [PMC]
Su CH, Kuo CL, Lu KW, Yu FS, Ma YS, Yang JL, et al. Fisetin-induced apoptosis of human oral cancer SCC-4 cells through reactive oxygen species production, endoplasmic reticulum stress, caspase-, and mitochondria-dependent signaling pathways.Environ Toxicol. 2017;32:1725–41. [DOI] [PubMed]
Park BS, Choi NE, Lee JH, Kang HM, Yu SB, Kim HJ, et al. Crosstalk between Fisetin-induced Apoptosis and Autophagy in Human Oral Squamous Cell Carcinoma.J Cancer. 2019;10:138–46. [DOI] [PubMed] [PMC]
Ravula AR, Teegala SB, Kalakotla S, Pasangulapati JP, Perumal V, Boyina HK. Fisetin, potential flavonoid with multifarious targets for treating neurological disorders: An updated review.Eur J Pharmacol. 2021;910:174492. [DOI] [PubMed]
Yousefzadeh MJ, Zhu Y, McGowan SJ, Angelini L, Fuhrmann-Stroissnigg H, Xu M, et al. Fisetin is a senotherapeutic that extends health and lifespan.EBioMedicine. 2018;36:18–28. [DOI] [PubMed] [PMC]
Kim SS, Harford JB, Pirollo KF, Chang EH. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.Biochem Biophys Res Commun. 2015;468:485–9. [DOI] [PubMed] [PMC]
Oberoi RK, Parrish KE, Sio TT, Mittapalli RK, Elmquist WF, Sarkaria JN. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.Neuro Oncol. 2016;18:27–36. [DOI] [PubMed] [PMC]
Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.Neuro Oncol. 2018;20:184–91. [DOI] [PubMed] [PMC]
Luo H, Shusta EV. Blood-Brain Barrier Modulation to Improve Glioma Drug Delivery.Pharmaceutics. 2020;12:1085. [DOI] [PubMed] [PMC]
Chen WS, Lee YJ, Yu YC, Hsaio CH, Yen JH, Yu SH, et al. Enhancement of p53-mutant human colorectal cancer cells radiosensitivity by flavonoid fisetin.Int J Radiat Oncol Biol Phys. 2010;77:1527–35. [DOI] [PubMed]
Khozooei S, Lettau K, Barletta F, Jost T, Rebholz S, Veerappan S, et al. Fisetin induces DNA double-strand break and interferes with the repair of radiation-induced damage to radiosensitize triple negative breast cancer cells.J Exp Clin Cancer Res. 2022;41:256. [DOI] [PubMed] [PMC]
Leu JD, Wang BS, Chiu SJ, Chang CY, Chen CC, Chen FD, et al. Combining fisetin and ionizing radiation suppresses the growth of mammalian colorectal cancers in xenograft tumor models.Oncol Lett. 2016;12:4975–82. [DOI] [PubMed] [PMC]
Mahoney SA, Venkatasubramanian R, Darrah MA, Ludwig KR, VanDongen NS, Greenberg NT, et al. Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence.Aging Cell. 2024;23:e14060. [DOI] [PubMed] [PMC]
Tavenier J, Nehlin JO, Houlind MB, Rasmussen LJ, Tchkonia T, Kirkland JL, et al. Fisetin as a senotherapeutic agent: Evidence and perspectives for age-related diseases.Mech Ageing Dev. 2024;222:111995. [DOI] [PubMed]
Zhang L, Tong X, Huang J, Wu M, Zhang S, Wang D, et al. Fisetin Alleviated Bleomycin-Induced Pulmonary Fibrosis Partly by Rescuing Alveolar Epithelial Cells From Senescence.Front Pharmacol. 2020;11:553690. [DOI]
Mir SA, Dar A, Hamid L, Nisar N, Malik JA, Ali T, et al. Flavonoids as promising molecules in the cancer therapy: An insight.Curr Res Pharmacol Drug Discov. 2023;6:100167. [DOI] [PubMed] [PMC]
Kashyap D, Garg VK, Tuli HS, Yerer MB, Sak K, Sharma AK, et al. Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential.Biomolecules. 2019;9:174. [DOI] [PubMed] [PMC]
Sak K, Kasemaa K, Everaus H. Potentiation of luteolin cytotoxicity by flavonols fisetin and quercetin in human chronic lymphocytic leukemia cell lines.Food Funct. 2016;7:3815–24. [DOI] [PubMed]
Bjørklund G, Oliinyk P, Khavrona O, Lozynska I, Lysiuk R, Darmohray R, et al. The Effects of Fisetin and Curcumin on Oxidative Damage Caused by Transition Metals in Neurodegenerative Diseases.Mol Neurobiol. 2025;62:1225–46. [DOI] [PubMed]
Buranrat B, Senggunprai L, Prawan A, Kukongviriyapan V. Fisetin-Induced Cell Death, Apoptosis, and Antimigratory Effects in Cholangiocarcinoma Cells.J Appl Pharm Sci. 2025; 15:96–105. [DOI]
Silva-Pinto PA, de Pontes JTC, Aguilar-Morón B, Canales CSC, Pavan FR, Roque-Borda CA. Phytochemical insights into flavonoids in cancer: Mechanisms, therapeutic potential, and the case of quercetin.Heliyon. 2025;11:e42682. [DOI] [PubMed] [PMC]
Hasan AMW, Al Hasan MS, Mizan M, Miah MS, Uddin MB, Mia E, et al. Quercetin Promises Anticancer Activity through PI3K-AKT-MTOR Pathway: A Literature Review.Pharmacol Res Nat Prod. 2025;7:100206. [DOI]
Singh Tuli H, Rath P, Chauhan A, Sak K, Aggarwal D, Choudhary R, et al. Luteolin, a Potent Anticancer Compound: From Chemistry to Cellular Interactions and Synergetic Perspectives.Cancers (Basel). 2022;14:5373. [DOI] [PubMed] [PMC]
Wang Q, Wang H, Jia Y, Ding H, Zhang L, Pan H. Luteolin reduces migration of human glioblastoma cell lines via inhibition of the p-IGF-1R/PI3K/AKT/mTOR signaling pathway.Oncol Lett. 2017;14:3545–51. [DOI] [PubMed] [PMC]
Taj S, Nagarajan B. Inhibition by quercetin and luteolin of chromosomal alterations induced by salted, deep-fried fish and mutton in rats.Mutat Res. 1996;369:97–106. [DOI] [PubMed]
Joshi P, Joshi S, Semwal D, Bisht A, Paliwal S, Dwivedi J, et al. Curcumin: An Insight into Molecular Pathways Involved in Anticancer Activity.Mini Rev Med Chem. 2021;21:2420–57. [DOI] [PubMed]
Mohs RC, Greig NH. Drug discovery and development: Role of basic biological research.Alzheimers Dement (N Y). 2017;3:651–7. [DOI] [PubMed] [PMC]
Shen J, Swift B, Mamelok R, Pine S, Sinclair J, Attar M. Design and Conduct Considerations for First-in-Human Trials.Clin Transl Sci. 2019;12:6–19. [DOI] [PubMed] [PMC]
Li Y, Meng Q, Yang M, Liu D, Hou X, Tang L, et al. Current trends in drug metabolism and pharmacokinetics.Acta Pharm Sin B. 2019;9:1113–44. [DOI] [PubMed] [PMC]
Cedeno-Serna J. Investigational New Drug (IND) Application.In: Translational Sports Medicine. Elsevier; 2023. pp. 419–24. [DOI]
Holbein ME. Understanding FDA regulatory requirements for investigational new drug applications for sponsor-investigators.J Investig Med. 2009;57:688–94. [DOI] [PubMed]
Sip S, Rosiak N, Sip A, Żarowski M, Hojan K, Cielecka-Piontek J. A Fisetin Delivery System for Neuroprotection: A Co-Amorphous Dispersion Prepared in Supercritical Carbon Dioxide.Antioxidants (Basel). 2023;13:24. [DOI] [PubMed] [PMC]
Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials.J Natl Cancer Inst. 2009;101:708–20. [DOI] [PubMed] [PMC]
